married ($p < 0.05$). Patients with methamphetamine dependence had a higher ratio of never being married ($p < 0.05$). Significant differences were found in cohabitation ($z = 62.71$, $p < 0.0001$). More patients with alcohol dependence lived with their family ($p < 0.05$). More patients with methamphetamine dependence lived with their parents ($p < 0.05$). Significant differences were found in years at their current residence ($z = 12.24$, $p = 0.002$). More patients with alcohol dependence had lived in their current residence for more than 10 years ($p < 0.05$). More patients with methamphetamine dependence had lived in their current residence for less than 10 years ($p < 0.05$). With regard to abuse, patients with methamphetamine dependence had a higher ratio of physical abuse experience ($z = 8.48$, $p = 0.0007$). With regard to psychiatric symptoms in the past month, patients with methamphetamine dependence had higher ratios of "hallucinations" ($z = 17.11$, $p = 0.0003$) and "trouble understanding, concentrating, or remembering" ($z = 16.57$, $p = 0.0002$). Patients with methamphetamine dependence had more convictions ($t = 5.35$, $p < 0.0001$).

Table 2. Participant characteristics.

Characteristic	Alcohol dependence ($n = 321$)	Methamphetamine dependence ($n = 68$)	p	
Mean age (years [SD])	49.46 (10.34)	34.82 (8.51)	< 0.0001	*
Education				
Education (mean years [SD])	11.75 (2.69)	11.87 (2.32)	n.s.	
% Junior high school graduate	29.91	14.71	< 0.05	*
% Some high school	9.66	25.00	< 0.05	*
% High school graduate	31.15	30.88	n.s.	
% Some college	7.48	11.76	n.s.	
% College graduate	18.38	13.24	n.s.	
% Unclear	3.43	4.41	n.s.	
Employment (past 3 years)				
% Full-time	69.47	41.18	< 0.05	*
% Part-time	10.59	25.00	< 0.05	*
% Retired	6.85	0.00	< 0.05	*
% Unemployed	10.90	25.00	< 0.05	*
% Other	2.18	8.82	< 0.05	*
% Public assistance recipient (past 30 days)	8.41	16.18	n.s.	
Marital status				
% Married	54.21	8.82	< 0.05	*
% Never married	21.18	66.18	< 0.05	*
% Separated/Widowed/Divorced	24.61	25.00	n.s.	
Cohabitation				
% With family	46.11	10.29	< 0.05	*
% With spouse	14.64	10.29	n.s.	
% With parents	13.40	39.71	< 0.05	*
% Alone	21.81	19.12	n.s.	
% Other	4.05	20.59	< 0.05	*

Table 2. *Cont.*

Characteristic	*Alcohol dependence (n = 321)*	*Methamphetamine dependence(n = 68)*	*p*	
Years of current cohabitation				
% < 10 years	41.32	65.57	< 0.05	*
% 10-20 years	22.08	11.48	< 0.05	*
% > 20 years	36.59	22.95	< 0.05	*
Abuse				
% Emotional abuse	22.19	14.93	0.25	
% Physical abuse	6.85	17.91	0.007	*
% Sexual abuse	0.00	0.00	-	
Psychiatric symptoms				
% Serious depression	15.26	14.71	1.00	
% Serious anxiety or tension	24.61	32.35	0.22	
% Hallucinations	2.80	14.71	0.0003	*
% Trouble understanding, concentrating, or remembering	12.46	32.35	0.0002	*
% Trouble controlling violent behavior	4.05	10.29	0.06	
% Serious thoughts of suicide	18.07	16.18	0.86	
% Attempted suicide	3.12	4.40	0.71	
Number of convictions (mean years [SD])	0.14 (0.74)	1.32 (1.79)	< 0.0001	*

SD, standard deviation; * significant difference.

3.2. Relationship between ASI Composite Scores

Table 3 shows the correlations between ASI CSs after controlling for age. For patients with alcohol dependence, the CS of psychiatric problems was significantly correlated with the CSs of drug use ($r = 0.27$, $p < 0.0001$) and family/social problems ($r = 0.28$, $p < 0.0001$). For patients with methamphetamine dependence, the CS of psychiatric problems was significantly correlated with the CSs of medical problems ($r = 0.33$, $p = 0.008$), employment/support problems ($r = 0.40$, $p = 0.001$), drug use ($r = 0.40$, $p = 0.0009$), and family/social problems ($r = 0.43$, $p = 0.0004$). The CS of family/social problems was significantly correlated with the CS of medical problems ($r = 0.33$, $p = 0.007$) and legal problems ($r = 0.35$, $p = 0.004$).

Table 3. Correlations between ASI composite scores after controlling for age.

Alcohol dependence		**Employment**	**Alcohol use**	**Drug use**	**Legal**	**Family/Social**	**Psychiatric**
Medical	*r*	0.08	−0.13	0.08	0.05	0.03	0
	p	0.2	0.03	0.16	0.38	0.62	0.97
Employment	*r*		0.01	0.07	0.13	0.12	−0.02
	p		0.85	0.26	0.02	0.04	0.69
Alcohol use	*r*			−0.04	0.01	0.14	0.09
	p			0.51	0.85	0.02	0.14
Drug use	*r*				0	0.14	0.26
	p				0.96	0.02	< 0.0001 *
Legal	*r*					0.02	−0.07
	p					0.69	0.23
Family/Social	*r*						0.28
	p						< 0.0001 *

Table 3. *Cont.*

Methamphetamine dependence		**Employment**	**Alcohol use**	**Drug use**	**Legal**	**Family/Social**	**Psychiatric**
Medical	r	0.17	0.04	−0.04	0.19	0.33	0.33
	p	0.17	0.76	0.78	0.12	0.007 *	0.008 *
Employment	r		−0.04	0.22	−0.01	0.05	0.40
	p		0.76	0.07	0.92	0.71	0.001 *
Alcohol use	r			0.12	−0.06	0.20	0.06
	p			0.34	0.61	0.11	0.65
Drug use	r				−0.05	0.07	0.40
	p				0.68	0.60	0.0009 *
Legal	r					0.35	0.09
	p					0.004 *	0.48
Family/Social	r						0.43
	p						0.0004 *

* Significant correlation ($p < 0.01$).

Table 4 shows the comparison of ratios of each psychiatric symptom in the past month between groups of high and low CSs of Family/Social relationship problems. These groups were divided on the basis of median CSs of Family/Social relationships. In patients with alcohol dependence, high CSs of Family/Social relationship problems was associated with higher ratios of serious depression ($z = 10.98$, $p = 0.001$), serious anxiety or tension ($z = 6.17$, $p = 0.02$), and serious thoughts of suicide ($z = 6.81$, $p = 0.01$) than the low CS group. In patients with methamphetamine dependence, no significant difference was found between groups of high and low CSs of Family/Social relationship problems in ratio of each psychiatric symptom.

Table 4. Comparison of ratios of each psychiatric symptom between groups of high and low CSs of Family/Social relationship problems.

Alcohol dependence	Family/Social			
	High	Low	p	
Serious depression (%)	22.62	9.41	0.001	*
Serious anxiety or tension (%)	32.56	19.08	0.02	*
Hallucinations (%)	2.33	3.82	0.72	
Trouble understanding, concentrating, or remembering (%)	14.73	12.21	0.59	
Trouble controlling violent behavior (%)	5.43	3.88	0.77	
Serious thoughts of suicide (%)	25.78	12.98	0.01	*
Attempted suicide (%)	3.10	3.08	1.00	

Table 4. *Cont.*

Methamphetamine dependence	Family/Social		
	High	Low	*p*
Serious depression (%)	21.88	6.06	0.08
Serious anxiety or tension (%)	39.39	24.24	0.29
Hallucinations (%)	18.18	12.12	0.73
Trouble understanding, concentrating, or remembering (%)	42.42	24.24	0.19
Trouble controlling violent behavior (%)	18.18	3.03	0.10
Serious thoughts of suicide (%)	18.18	12.12	0.73
Attempted suicide (%)	3.03	3.03	1.00

* Significant difference.

3.3. Family History of Alcohol Dependence, Methamphetamine Dependence, and Psychiatric Disorders

Table 5 shows the family histories of alcohol dependence, methamphetamine dependence, and psychiatric disorders in the participants of the present study. Of the patients with alcohol dependence, 36.33% had fathers with alcohol-related problems, 20.87% had uncles (paternal) with alcohol-related problems, and 25.94% had brothers with alcohol-related problems, and these ratios were significantly higher compared with patients with methamphetamine dependence (father, $z = 7.97$, $p = 0.005$; uncle, $z = 6.31$, $p = 0.009$; brother, $z = 8.81$, $p = 0.002$). Of the patients with methamphetamine dependence, 9.52% had brothers with drug-related problems, and the ratio was significantly higher than that of patients with alcohol dependence ($z = 22.90$, $p = 0.005$).

Table 5. Family history of alcohol dependence, methamphetamine dependence, and psychiatric disorders.

Relation	**Alcohol dependence**	**Methamphetamine dependence**	*p*
Grandmother (maternal) (%)			
Alcohol	1.44	2.04	0.57
Drug	0.00	0.00	—
Psychiatric disorder	0.00	0.00	—
Grandfather (maternal) (%)			
Alcohol	15.42	6.12	0.11
Drug	0.00	0.00	—
Psychiatric disorder	0.00	0.00	—
Mother (%)			
Alcohol	1.30	1.92	0.54
Drug	0.33	0.00	1.00
Psychiatric disorder	2.64	7.41	0.09

Table 5. *Cont.*

Relation	Alcohol dependence	Methamphetamine dependence	p	
Aunt (maternal) (%)				
Alcohol	2.83	2.04	1.00	
Drug	0.41	2.08	0.30	
Psychiatric disorder	0.41	2.04	0.31	
Uncle (maternal) (%)				
Alcohol	14.45	6.00	0.17	
Drug	0.79	0.00	1.00	
Psychiatric disorder	1.19	3.92	0.20	
Sisters (%)				
Alcohol	3.73	2.44	1.00	
Drug	0.00	2.50	0.14	
Psychiatric disorder	2.93	2.50	1.00	
Grandmother (paternal) (%)				
Alcohol	1.47	0.00	1.00	
Drug	0.00	1.96	0.20	
Psychiatric disorder	0.98	3.85	0.18	
Grandfather (paternal) (%)				
Alcohol	18.37	7.84	0.09	
Drug	0.00	1.96	0.20	
Psychiatric disorder	0.50	1.96	0.37	
Father (%)				
Alcohol	36.33	16.67	0.005	*
Drug	1.02	0.00	1.00	
Psychiatric disorder	1.72	0.00	1.00	
Aunt (paternal) (%)				
Alcohol	3.45	0.00	0.36	
Drug	0.00	0.00	-	
Psychiatric disorder	0.87	2.08	0.44	
Uncle (paternal) (%)				
Alcohol	20.87	5.88	0.009	*
Drug	0.00	1.96	0.18	
Psychiatric disorder	0.44	0.00	1.00	
Brothers (%)				
Alcohol	25.94	4.88	0.002	*
Drug	0.00	9.52	0.0005	*
Psychiatric disorder	1.68	4.88	0.22	

* Significant difference.

3.4. Comparisons of Family Relationships between Patients with Alcohol Dependence and Patients with Methamphetamine Dependence

In the Family/Social relationship domain, patients answered "Yes," "No," or "Neither" about whether they had a close, long-lasting, personal relationship with family members, partners, or friends in their life. Participants who answered "Yes" were assigned to the "good relationships group," and participants who answered "No" were assigned to the "bad relationships group." In the comparison of

experience of good relationships with family members (Table 6), patients with alcohol dependence had a significantly higher ratio of experience of good relationships with their father ($z = 17.77$, $p < 0.0001$).

Table 6. Comparisons of the ratios of good family relationships between patients with alcohol dependence and patients with methamphetamine dependence.

	Alcohol dependence	**Methamphetamine dependence**	*p*	
Mother (%)	76.07	64.71	0.07	
Father (%)	70.55	43.08	< 0.0001	*
Brothers/sisters (%)	72.43	60.66	0.09	
Partner (%)	62.89	58.00	0.52	
Children (%)	72.29	53.33	0.14	
Friends (%)	77.74	69.49	0.18	

* Significant difference.

3.5. Comparison of Severity of Addiction between Good and Bad Family Relationships

Tables 7 and 8 show the comparisons of ASI CSs between good and bad family relationships. Patients with alcohol dependence who experienced bad relationships with their brothers and sisters ($t = 2.99$, $p = 0.003$) and partners ($t = 3.47$, $p = 0.0006$) had a higher CS of employment/support problems. Patients who experienced bad relationships with their partners had a higher CS of family/social problems ($t = 4.90$, $p < 0.0001$). Patients who experienced bad relationships with their mothers ($t = 2.73$, $p = 0.02$), fathers ($t = 2.84$, $p = 0.01$), brothers and sisters ($t = 2.82$, $p = 0.005$), and friends ($t = 2.99$, $p = 0.02$) had a higher CS of psychiatric problems. In patients with methamphetamine dependence, no significant difference was found between good and bad family relationships in ASI CSs.

Table 7. Comparison of severity of addiction between good and bad family relationships in patients with alcohol dependence.

	Mother				**Father**			
	Good relationship	**Bad relationship**	*p*		**Good relationship**	**Bad relationship**	*p*	
Medical	0.22 (0.29)	0.29 (0.33)	0.12		0.22 (0.28)	0.29 (0.34)	0.14	
Employment	0.53 (0.28)	0.55 (0.29)	0.64		0.53 (0.29)	0.55 (0.27)	0.60	
Alcohol use	0.55 (0.22)	0.54 (0.22)	0.63		0.55 (0.23)	0.55 (0.23)	0.78	
Drug use	0.01 (0.04)	0.01 (0.03)	0.80		0.01 (0.04)	0.01 (0.03)	0.66	
Legal	0.004 (0.03)	0.01 (0.05)	0.42		0.004 (0.03)	0.004 (0.04)	0.99	
Family/Social	0.23 (0.22)	0.25 (0.21)	0.57		0.23 (0.22)	0.23 (0.20)	0.88	
Psychiatric	0.13 (0.18)	0.20 (0.24)	0.01	*	0.12 (0.18)	0.20 (0.23)	0.01	*

Table 7. *Cont.*

	Brothers and Sisters				Partner			
	Good relationship	Bad relationship	*p*		Good relationship	Bad relationship	*p*	
Medical	0.22 (0.29)	0.26 (0.32)	0.30		0.26 (0.31)	0.27 (0.31)	0.77	
Employment	0.51 (0.27)	0.61 (0.30)	0.00	*	0.48 (0.29)	0.60 (0.27)	0.00	*
Alcohol use	0.53 (0.22)	0.57 (0.23)	0.18		0.55 (0.22)	0.53 (0.22)	0.46	
Drug use	0.01 (0.04)	0.01 (0.04)	0.60		0.01 (0.04)	0.01 (0.04)	0.26	
Legal	0.003 (0.03)	0.01 (0.05)	0.32		0.005 (0.04)	0.01 (0.04)	0.67	
Family/Social	0.22 (0.22)	0.26 (0.19)	0.17		0.19 (0.19)	0.33 (0.23)	0.00	*
Psychiatric	0.13 (0.17)	0.20 (0.25)	0.02	*	0.13 (0.18)	0.17 (0.22)	0.09	
	Children				**Friends**			
	Good relationship	Bad relationship	*p*		Good relationship	Bad relationship	*p*	
Medical	0.25 (0.31)	0.32 (0.32)	0.11		0.24 (0.30)	0.31 (0.34)	0.15	
Employment	0.50 (0.30)	0.56 (0.27)	0.13		0.51 (0.29)	0.59 (0.29)	0.07	
Alcohol use	0.54 (0.23)	0.55 (0.21)	0.81		0.55 (0.22)	0.55 (0.22)	1.00	
Drug use	0.01 (0.04)	0.004 (0.02)	0.38		0.01 (0.04)	0.01 (0.02)	0.43	
Legal	0.003 (0.02)	0.01 (0.04)	0.52		0.004 (0.03)	0.01 (0.05)	0.36	
Family/Social	0.22 (0.22)	0.27 (0.19)	0.14		0.23 (0.21)	0.23 (0.22)	0.82	
Psychiatric	0.13 (0.19)	0.15 (0.21)	0.70		0.13 (0.18)	0.22 (0.26)	0.02	*

* Significant difference.

Table 8. Comparison of severity of addiction between good and bad family relationships in patients with methamphetamine dependence.

	Mother			Father		
	Good relationship	Bad relationship	*p*	Good relationship	Bad relationship	*p*
Medical	0.05 (0.17)	0.13 (0.24)	0.21	0.04 (0.13)	0.12 (0.25)	0.08
Employment	0.67 (0.22)	0.74 (0.25)	0.28	0.70 (0.21)	0.70 (0.25)	0.99
Alcohol use	0.12 (0.19)	0.19 (0.27)	0.26	0.10 (0.20)	0.16 (0.23)	0.27
Drug use	0.09 (0.09)	0.12 (0.12)	0.27	0.08 (0.09)	0.12 (0.11)	0.19
Legal	0.02 (0.07)	0.04 (0.13)	0.29	0.01 (0.06)	0.03 (0.11)	0.32
Family/Social	0.14 (0.13)	0.23 (0.20)	0.05	0.13 (0.13)	0.21 (0.18)	0.06
Psychiatric	0.23 (0.24)	0.32 (0.27)	0.17	0.24 (0.23)	0.30 (0.27)	0.34
	Brothers/Sisters			**Partner**		
	Good relationship	Bad relationship	*p*	Good relationship	Bad relationship	*p*
Medical	0.05 (0.14)	0.12 (0.24)	0.18	0.08 (0.20)	0.05 (0.14)	0.54
Employment	0.66 (0.21)	0.77 (0.25)	0.08	0.62 (0.26)	0.73 (0.21)	0.10
Alcohol use	0.10 (0.19)	0.21 (0.26)	0.08	0.19 (0.24)	0.13 (0.24)	0.43
Drug use	0.09 (0.09)	0.12 (0.12)	0.31	0.09 (0.12)	0.09 (0.09)	0.93
Legal	0.02 (0.08)	0.04 (0.11)	0.51	0.04 (0.11)	0.002 (0.01)	0.09
Family/Social	0.15 (0.16)	0.23 (0.17)	0.07	0.18 (0.14)	0.17 (0.14)	0.80
Psychiatric	0.23 (0.26)	0.30 (0.24)	0.36	0.24 (0.26)	0.24 (0.23)	0.94

Table 8. *Cont.*

	Children			Friends		
	Good relationship	**Bad relationship**	*p*	**Good relationship**	**Bad relationship**	*p*
Medical	0.11 (0.20)	0.07 (0.19)	0.71	0.08 (0.21)	0.09 (0.20)	0.77
Employment	0.54 (0.34)	0.66 (0.27)	0.42	0.69 (0.24)	0.69 (0.23)	0.94
Alcohol use	0.16 (0.18)	0.34 (0.34)	0.24	0.13 (0.21)	0.17 (0.25)	0.55
Drug use	0.04 (0.06)	0.07 (0.11)	0.52	0.09 (0.10)	0.12 (0.12)	0.46
Legal	0.03 (0.09)	0.00 (0.00)	0.42	0.02 (0.09)	0.04 (0.11)	0.62
Family/Social	0.15 (0.13)	0.15 (0.12)	0.89	0.18 (0.15)	0.16 (0.16)	0.69
Psychiatric	0.14 (0.19)	0.14 (0.19)	0.97	0.28 (0.24)	0.69	

* Significant difference.

4. Discussion

With regard to the comparisons of family relationships between patients with alcohol dependence and patients with methamphetamine dependence, patients with methamphetamine dependence had difficulty developing good relationships with their father. With regard to the association between good relationships and the severity of substance dependence, in patients with alcohol dependence, bad relationships with parents, brothers and sisters, and friends were related to severe psychiatric problems. Bad relationships with brothers and sisters and partners were related to severe employment/support problems. Bad relationships with partners were related to severe family/social problems. In patients with methamphetamine dependence, no association was found between relationships and severity of substance dependence.

With regard to the associations between ASI CSs, psychiatric problems were related to drug use and family/social relationships in patients with alcohol dependence, and psychiatric problems were related to medical, employment/support, and family/social relationship problems in patients with methamphetamine dependence. In patients with alcohol dependence, relationships with various family members and friends were related to their mental condition, and bad relationships with their partners may be heavily involved in their difficult interpersonal relationships. Because problems with family/social relationships were related to psychiatric problems, bad relationships with their partners may be involved in psychiatric problems through their difficulties with interpersonal relationships. Additionally, the association between psychiatric problems and drug use in patients with alcohol dependence may be affected by the drugs prescribed for their psychiatric problems. Notably, some patients with alcohol dependence reported dependence on barbiturates or other analgesics/ hypnotics/tranquilizers. Moreover, a deterioration of psychiatric problems may be involved in increased medical problems, employment/support problems, and drug use problems. These results suggest that although the ASI was developed to independently evaluate each of these seven problem areas [12], family relationships may be particularly related to psychiatric problems. Moreover, with regard to the associations between family/social relationships and specific symptoms, bad family/social relationships in alcohol dependence were related to the presence of serious depression, serious anxiety or tension, and serious thoughts of suicide, and bad family/social relationships in methamphetamine dependence were not related to the presence of specific psychiatric symptoms. Bad

family/social relationships in patients with alcohol dependence and patients with methamphetamine dependence may be differentially related to psychiatric problems. Investigating the association between family relationships and psychiatric disorders may be useful, based on the relationship between family/social relationships and psychiatric status found in the present study.

The average age of the patients with alcohol dependence was higher than the average age of the patients with methamphetamine dependence, suggesting that having a long-term residence may be attributable to the higher average age of the patients with alcohol dependence. With regard to educational background, the higher ratio of junior high school graduation in patients with alcohol dependence may be attributable to the age group of patients with alcohol dependence, which contained many older patients. The higher ratio of being a high school dropout in patients with methamphetamine dependence may reflect their difficulty maintaining their relationships or completing their schoolwork on school days. With regard to employment status, the higher ratio of retirement in patients with alcohol dependence may be attributable to their higher average age, and the higher ratios of part-time employment and unemployment in patients with methamphetamine dependence may reflect their difficulty retaining a job. With regard to abuse experience, the higher ratio of being a victim of physical abuse in patients with methamphetamine dependence may make developing a trusting relationship with someone difficult. Consistent with this possibility, a previous study suggested that male victims of physical and sexual abuse have difficulties seeking and retaining gainful employment, trusting others, developing intimate relationships, and regulating their anger and behavior [14]. The higher number of convictions in patients with methamphetamine dependence suggests that methamphetamine dependence is complicated by antisocial personality disorder.

With regard to family histories of alcohol dependence, drug dependence, and psychiatric disorders, patients with alcohol dependence had higher ratios of having a father, paternal uncle, and brother with alcohol-related problems. Patients with methamphetamine dependence had higher ratios of having a brother with drug-related problems. These significant results were found only with male relatives, and substance (alcohol or drug) use that became a problem for patients was common when substances were used by their male relatives. However, because these results may have been affected by the high prevalence of individuals with alcohol or drug dependence in the male population [15], these results should be interpreted with caution. Additionally, information about antisocial characteristics among not only the patients but also their families may be worth collecting in future studies to ascertain differences in the interactions between parents and children with substance dependence.

Based on the above results from patients with alcohol dependence, unestablished family relationships over time influenced a wide range of problems, especially the severity of psychiatric problems. This result suggests the usefulness of psychological therapy for treating family dysfunction and self-help group therapy. In patients with methamphetamine dependence, unestablished relationships with their father over the years may not have been linked to their present severity of substance dependence in ASI CSs. Moreover, not simply relationships with specific family members but overall family/social relationships may be related to severity in ASI CSs (e.g., Psychiatric, Medical, and Legal problems). Given the result that patients with methamphetamine dependence often lived with their parents, investigating the effect of bad relationships with their father on relationships with their brother with drug-related problems may be important. Furthermore, verifying the possibility that

patients with methamphetamine dependence may not often establish good relationships with their father because of their experiences of abuse by their parents may be meaningful in future studies.

A previous study suggested the importance of distinguishing between alcohol and drug dependence disorders and examining their differential etiological pathways [16]. The present study may also suggest the necessity of separately investigating the association between family relationships and various problems related to substance dependence in alcohol dependence and methamphetamine dependence. The results of the present study may provide support for the possibility that the results of the ASI as an intake instrument may be an indicator of early intervention for family and social problems, and personalized programs that augment usual interventions may be useful.

Although this study provided useful new insights, it has a few limitations. First, the sample did not contain female patients. Role differences in a family may exist between males and females. Future studies should assess female patients. Second, the uniformity of the participants in this study may be problematic, including differences in age and present status (*i.e.*, inpatient, outpatient, or recovering individual) between the alcohol dependence group and methamphetamine dependence group. Third, this study utilized a cross-sectional design, so we could not establish a causal relationship between family relationships and problems related to alcohol or drug dependence. However, the results of this study may be beneficial for future longitudinal studies.

Acknowledgements

We acknowledge Michael Arends for his assistance with editing the manuscript. This work was supported by grants from the MHLW of Japan (H19-iyaku-023, H22-iyaku-015), MEXT of Japan (20730467, 23730687), Smoking Research Foundation, and Mitsubishi Foundation for Social Welfare Activities.

References

1. Osaki, Y.; Matsushita, S.; Shirasaka, T.; Hiro, H.; Higuchi, S. Nationwide survey of alcohol drinking and alcoholism among Japanese adults. *Nihon Arukoru Yakubutsu Igakkai Zasshi* **2005**, *40*, 455-470.
2. Ikeda, K.; Yamamoto, H.; Takamatsu, Y.; Haraguchi, A.; Umeno, M.; Senoo, E. New approaches toward treatment of methamphetamine dependence. *Seishin Igaku* **2004**, *46*, 57-72.
3. Ministry of Justice Research and Training Institute. *White Paper on Crime in Japan 2003*; Ministry of Finance Printing Bureau: Tokyo, Japan, 2004; pp. 305-314.
4. Hamdan-Mansour, A.M.; Puskar, K.; Sereika, S.M. Perceived social support, coping strategies and alcohol use among rural adolescents/USA sample. *Int. J. Ment. Health Addict.* **2007**, *5*, 53-64.
5. Wills, T.A.; Sandy, J.M.; Yaeger, A.M.; Cleary, S.D.; Shinar, O. Coping dimensions, life stress, and adolescent substance use: a latent growth analysis. *J. Abnorm. Psychol.* **2001**, *110*, 309-323.
6. Thoits, P.A. Stress, coping, and social support processes: Where are we? What next? *J. Health. Soc. Behav.* **1995**, *35*, 53-79.
7. Rowe, C.L.; Multidimensional family therapy: addressing co-occurring substance abuse and other problems among adolescents with comprehensive family-based treatment. *Child Adolesc. Psychiatr. Clin. N. Am.* **2010**, *19*, 563-576.

8. Costello, J.E.; Sung, M.; Worthman, C.; Angol, A. Pubertal maturation and the development of alcohol use and abuse. *Drug Alcohol Depend.* **2007**, *88 (Suppl. 1)*, S50-S59.
9. De Micheli, D.; Formigoni, M.L. Are reasons for the first use of drugs and family circumstances predictors of future use patterns? *Addict. Behav.* **2002**, *27*, 87-100.
10. McLellan, A.T.; Kushner, H.; Metzger, D.; Peters, R.; Smith, I.; Grissom, G.; Pettinati, H.; Argeriou, M. The fifth edition of the Addiction Severity Index. *J. Subst. Abuse Treat.* **1992**, *9*, 199-213.
11. Senoo, E.; Ogai, Y.; Haraguchi, A.; Kondo, A.; Ishibashi, Y.; Umeno, M.; Kikumoto, H.; Hori, T.; Komiyama, T.; Kato, R.; *et al.* Reliability and validity of the Japanese version of the Addiction Severity Index (ASI-J). *Nihon Arukoru Yakubutsu Igakkai Zasshi* **2006**, *41*, 368-379.
12. Haraguchi, A.; Ogai, Y.; Senoo, E.; Saito, S.; Suzuki, Y.; Yoshino, A.; Ino, A.; Yanbe, K.; Hasegawa, M.; Murakami, M. *et al.* Verification of the Addiction Severity Index Japanese Version (ASI-J) as a treatment-customization, prediction, and comparison tool for alcohol-dependent individuals. *Int. J. Environ. Res. Public Health* **2009**, *6*, 2205-2225.
13. ASI Manual (Question by Question Guide). Treatment Research Solutions Group Website. Available online: http://www.tresearch.org/resources/manuals/ASIQbyQGuide.pdf (accessed on 1 October 2011).
14. Romano, E.; De Luca, R.V. Male sexual abuse: a review of effects, abuse characteristics, and links with later psychological functioning. *Aggress. Violent Behav.* **2001**, *6*, 55-78.
15. Ministry of Health, Labour and Welfare of Japan. *Patients Survey*; Ministry of Health, Labour and Welfare of Japan: Tokyo, Japan, 2008.
16. Zhou, Q.; King, K.M.; Chassin, L. The roles of familial alcoholism and adolescent family harmony in young adults' substance dependence disorders: mediated and moderated relations. *J. Abnorm. Psychol.* **2006**, *115*, 320-331.

© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

Inhibition of G Protein-Activated Inwardly Rectifying K^+ Channels by Different Classes of Antidepressants

Toru Kobayashi[1,2]*, Kazuo Washiyama[1], Kazutaka Ikeda[2]

1 Department of Project Programs, Center for Bioresource-based Researches, Brain Research Institute, Niigata University, Niigata, Japan, 2 Research Project for Addictive Substances, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

Abstract

Various antidepressants are commonly used for the treatment of depression and several other neuropsychiatric disorders. In addition to their primary effects on serotonergic or noradrenergic neurotransmitter systems, antidepressants have been shown to interact with several receptors and ion channels. However, the molecular mechanisms that underlie the effects of antidepressants have not yet been sufficiently clarified. G protein-activated inwardly rectifying K^+ (GIRK, Kir3) channels play an important role in regulating neuronal excitability and heart rate, and GIRK channel modulation has been suggested to have therapeutic potential for several neuropsychiatric disorders and cardiac arrhythmias. In the present study, we investigated the effects of various classes of antidepressants on GIRK channels using the *Xenopus* oocyte expression assay. In oocytes injected with mRNA for GIRK1/GIRK2 or GIRK1/GIRK4 subunits, extracellular application of sertraline, duloxetine, and amoxapine effectively reduced GIRK currents, whereas nefazodone, venlafaxine, mianserin, and mirtazapine weakly inhibited GIRK currents even at toxic levels. The inhibitory effects were concentration-dependent, with various degrees of potency and effectiveness. Furthermore, the effects of sertraline were voltage-independent and time-independent during each voltage pulse, whereas the effects of duloxetine were voltage-dependent with weaker inhibition with negative membrane potentials and time-dependent with a gradual decrease in each voltage pulse. However, Kir2.1 channels were insensitive to all of the drugs. Moreover, the GIRK currents induced by ethanol were inhibited by sertraline but not by intracellularly applied sertraline. The present results suggest that GIRK channel inhibition may reveal a novel characteristic of the commonly used antidepressants, particularly sertraline, and contributes to some of the therapeutic effects and adverse effects.

Citation: Kobayashi T, Washiyama K, Ikeda K (2011) Inhibition of G Protein-Activated Inwardly Rectifying K^+ Channels by Different Classes of Antidepressants. PLoS ONE 6(12): e28208. doi:10.1371/journal.pone.0028208

Editor: Kenji Hashimoto, Chiba University Center for Forensic Mental Health, Japan

Received September 1, 2011; **Accepted** November 3, 2011; **Published** December 2, 2011

Copyright: © 2011 Kobayashi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by research grants from the Ministry of Education, Culture, Sports Science and Technology of Japan and the Ministry of Health, Labour and Welfare of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: torukoba@bri.niigata-u.ac.jp

Introduction

Depression is one of the most common illnesses in the world [1,2]. After the efficacy of tricyclic antidepressants (TCAs), including imipramine, amitriptyline and amoxapine, was well established, various classes of antidepressants were introduced, including selective serotonin reuptake inhibitors (SSRIs; fluoxetine, paroxetine and sertraline), serotonin-norepinephrine reuptake inhibitors (SNRIs; venlafaxine and duloxetine), selective norepinephrine reuptake inhibitors (NRIs; reboxetine), noradrenergic and specific serotonergic antidepressants (NaSSAs; mirtazapine and mianserin), and 5-hydroxytryptamine type 2 (5-HT_2) receptor antagonists (nefazodone) [1–3]. Antidepressants are commonly used for the treatment of depression and several neuropsychiatric disorders, such as anxiety disorders, eating disorders, obsessive-compulsive disorders, and chronic pain disorders [1–3]. Their clinical efficacy is hypothesized to be linked mainly with facilitation of noradrenergic or serotonergic function in the brain [2]. In contrast, the interaction between antidepressants and muscarinic, α_1 adrenergic, and H_1 histamine receptors is involved in some of their adverse side effects, such as dry mouse, orthostatic hypotension, and sedation [2]. Antidepressants have also been shown to modulate the function of several other receptors and ion channels, including 5-HT_{2C} and 5-HT_3 receptors, nicotinic acetylcholine receptors, *N*-methyl-D-aspartate (NMDA) receptor channels, $P2X_2$ receptors, voltage-gated Ca^{2+}, Na^+, and K^+ channels, Ca^{2+}-activated K^+ channels, two-pore-domain K^+ channels, and volume regulated anion channels [4–23]. The modulation of these receptors and channels might also be relevant to the pharmacological effects of antidepressants. However, the molecular mechanisms that underlie the effects of various antidepressants have not yet been sufficiently clarified.

G protein-activated inwardly rectifying K^+ (GIRK) channels (also known as Kir3 channels) are members of a major subfamily of inwardly rectifying K^+ (Kir) channels that includes seven subfamilies [24]. Four GIRK channel subunits have been identified in mammals [25–27]. Neuronal GIRK channels are predominantly heterotetramers composed of GIRK1 and GIRK2 subunits in most brain regions or homotetramers composed of GIRK2 subunits in the substantia nigra [27–30], whereas atrial GIRK channels are heterotetramers composed of GIRK1 and GIRK4 subunits [26]. The channels are activated by various $G_{i/o}$-protein-coupled receptors, such as M_2 muscarinic, α_2 adrenergic, D_2 dopaminergic, opioid, nociceptin/orphanin FQ, CB_1 cannabinoid, and A_1 adenosine receptors, through the direct action of G-protein $\beta\gamma$ subunits [31–33]. Additionally, ethanol activates GIRK

channels independently of G-protein-coupled signaling pathways [34,35]. GIRK channels play an important role in regulating neuronal excitability, synaptic transmission, and heart rate [31,36–39]. Furthermore, recent studies have suggested that GIRK channel modulation has the potential for treating several neuropsychiatric disorders and cardiac arrhythmias [33,40,41]. Therefore, GIRK channel modulators may affect various brain and cardiac functions. We have demonstrated the distinctive effects of several antidepressants on GIRK channels, even among the same class, particularly SSRIs [42,43]. To further clarify the interaction between various classes of commonly used antidepressants and GIRK channels may be useful for advancing our understanding of the pharmacological effects of antidepressants. In the present study, we examined the effects of various antidepressants on GIRK channels using the *Xenopus* oocyte expression assay.

Materials and Methods

Preparation of specific mRNAs

Plasmids that contain the entire coding sequences for the mouse GIRK1, GIRK2, and GIRK4 channel subunits were obtained previously [34,44,45]. cDNAs for mouse Kir2.1 in pcDNA1 [46] were generously provided by Dr. Lily Y. Jan (University of California, San Francisco). These plasmids were linearized by digestion with the appropriate enzymes as described previously [45,46]. The specific mRNAs were synthesized *in vitro* using the mMESSAGE mMACHINE™ *In Vitro* Transcription Kit (Ambion, Austin, TX, USA).

Electrophysiological analysis

Adult female *Xenopus laevis* frogs (Copacetic, Soma, Aomori, Japan) were anesthetized by immersion in water that contained 0.15% tricaine (Sigma-Aldrich, St. Louis, MO, USA). A small incision was made on the abdomen to remove several ovarian lobes from the frogs, which were humanely killed after the final collection. All procedures for the care and treatment of animals were performed in accordance with National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committee of Niigata University (Permit Number: 172-2). *Xenopus* oocytes (Stages V and VI) were manually isolated from the ovary and maintained in Barth's solution [47]. Oocytes were injected with mRNA for GIRK1/GIRK2 or GIRK1/GIRK4 combinations (0.15 ng each) or Kir2.1 (0.3 ng). The oocytes were incubated at 19°C in Barth's solution and manually defolliculated after treatment with 0.8 mg/ml collagenase (Wako Pure Chemical Industries, Osaka, Japan) for 1 h. The whole-cell currents of the oocytes were recorded from 3 to 9 days after injection with a conventional two-electrode voltage clamp [34,48]. The membrane potential was held at −70 mV unless otherwise specified. Microelectrodes were filled with 3 M KCl. The oocytes were placed in a 0.05 ml narrow chamber and continuously superfused with a high-potassium (hK) solution (96 mM KCl, 2 mM NaCl, 1 mM $MgCl_2$, 1.5 mM $CaCl_2$ and 5 mM HEPES, pH 7.4 with KOH) or a K^+-free high-sodium (ND98) solution (98 mM NaCl, 1 mM $MgCl_2$, 1.5 mM $CaCl_2$ and 5 mM HEPES, pH 7.4 with NaOH) at a flow rate of 2.5 ml/min. In the hK solution, the K^+ equilibrium potential was close to 0 mV, and the inward K^+ current flow through the Kir channels was observed at negative holding potentials as previously shown [25,27,43]. Additionally, to examine the effects of antidepressants on outward K^+ currents, a perfusion solution that contained 4 mM K^+ (K4 solution) was made by substituting NaCl with KCl in the ND98 solution. To examine the effects of an antidepressant on GIRK channels activated by G-protein activation, 13.8 nl of 100 mM Li_4-guanosine-5′-*O*-(3-thiotriphosphate) (GTPγS; Sigma-Aldrich), a nonhydrolyzable G-protein activator, dissolved in distilled water was injected into an oocyte using a nanoliter injector (World Precision Instruments, Sarasota, FL, USA) as described previously [49]. Furthermore, to examine the effects of intracellular sertraline, 23 nl of 10 mM sertraline dissolved in distilled water was injected into an oocyte using a Nanoliter injector as described previously [50], and the oocyte currents were then continuously recorded for approximately 30–40 min. Because the volume of the *Xenopus* oocytes used was approximately 1 µl, the intracellular concentration of sertraline was presumed to be approximately 225 µM. For the analysis of concentration-response relationships, the data were fitted to a standard logistic equation [51] using KaleidaGraph (Synergy Software, Reading, PA, USA). The concentration of a drug that produces 50% of the maximal current response for that drug (EC_{50}), the concentrations required to reduce control currents by 25% and 50% (IC_{25} and IC_{50}, respectively), and the Hill coefficient (n_H) were obtained from the concentration-response relationships.

Data analyses

The data are expressed as mean ± SEM, and *n* is the number of oocytes tested. The statistical analysis of differences between groups was performed using paired *t*-test, one-way analysis of variance (ANOVA), or two-way ANOVA followed by the Tukey-Kramer *post hoc* test. Values of $P<0.05$ were considered statistically significant.

Compounds

All of the antidepressants tested were commercially purchased. Amoxapine and nefazodone hydrochloride were obtained from Sigma-Aldrich. Mirtazapine and mianserin hydrochloride were obtained from Tocris Bioscience (Bristol, UK). Sertraline hydrochloride and duloxetine hydrochloride were obtained from Tronto Research Chemicals (North York, Canada). Venlafaxine hydrochloride was obtained from LKT Laboratories (St. Paul, MN, USA). Sertraline was dissolved in dimethyl sulfoxide (DMSO) or distilled water, and venlafaxine was dissolved in distilled water. The other antidepressants were dissolved in DMSO. The stock solution of each compound was stored at −30°C until use. Ethanol was purchased from Wako Pure Chemical Industries. Each compound was added to the perfusion solution in appropriate amounts immediately before the experiments.

Results

Inhibition of GIRK channels by antidepressants

In *Xenopus* oocytes injected with GIRK1 and GIRK2 mRNAs, basal GIRK currents, which depend on free G-protein βγ subunits present in the oocytes because of the inherent activity of G-proteins [32], were observed at a holding potential of −70 mV in an hK solution that contained 96 mM K^+ (Fig. 1A). The 3 mM Ba^{2+}-sensitive current components (1042.8±90.1 nA, $n=30$) correspond to the magnitude of GIRK currents in oocytes that express GIRK channels [34]. Extracellular application of 30 µM sertraline, an SSRI, reversibly reduced the inward currents through the expressed GIRK channels (Fig. 1A). The current responses to an additional 100 µM sertraline during the application of 3 mM Ba^{2+}, which blocks Kir channels, were not significant (reduction of inward currents by 4.5±3.5 nA; less than 1% inhibition of the Ba^{2+}-sensitive current components, $n=4$). Sertraline at 100 µM produced no significant response in a K^+-free ND98 perfusion solution that contained 98 mM Na^+ instead of the hK solution (3.0±1.8 nA, $n=4$), suggesting that the SSRI-sensitive current components show K^+ selectivity. Additionally, the application of DMSO or distilled water, the solvent vehicles, at the

highest concentration (0.3%) induced no significant current response in the hK or ND98 solutions ($n = 5$; data not shown). In contrast, in oocytes injected with mRNA for Kir2.1, a constitutively active Kir channel [46], extracellular application of 300 μM sertraline had no significant effect on the inward currents through the channels in the hK solution (less than 2% change of the Ba^{2+}-sensitive current components; 848.3±322.0 nA, $n = 4$; Fig. 1B). In uninjected oocytes, 300 μM sertraline and 3 mM Ba^{2+} caused no significant response (2.0±2.0 nA, $n = 4$, and 3.1±1.7 nA, $n = 4$, respectively; Fig. 1C) compared with oocytes injected with GIRK mRNA, suggesting no significant effect of sertraline or Ba^{2+} on intrinsic oocyte channels. Furthermore, in oocytes injected with GIRK1 and GIRK4 mRNAs, 30 μM sertraline similarly inhibited basal GIRK currents under the same conditions (51.6±4.3% inhibition of 3 mM Ba^{2+}-sensitive current components, 561.7±58.2 nA, $n = 11$). Additionally, the Ba^{2+}-sensitive current components in oocytes injected with mRNA for GIRK1/GIRK2 or GIRK1/GIRK4 combinations were very significantly larger than those in oocytes injected with the same small amount of a single GIRK mRNA (less than 20 nA, $n = 7$, respectively). The results indicate that sertraline predominantly inhibited GIRK1/2 and GIRK1/4 heteromultimeric channels, but not Kir2.1 channels. Moreover, the effects of different classes of antidepressants on GIRK channels were examined using the same expression assay. Amoxapine, a second generation TCA, and duloxetine, an SNRI, significantly inhibited basal GIRK currents at 100 μM (45.6±4.4 and 65.6±1.0% inhibition for GIRK1/2, $n = 5$ and 7, respectively; 27.6±4.0 and 49.7±2.2% inhibition for GIRK1/4, $n = 4$ and 6, respectively). However, the 5-HT_2 receptor antagonist nefazodone, NaSSAs mianserin and mirtazapine, and SNRI venlafaxine weakly inhibited the currents at 100 μM (35.9±3.5, 24.1±5.5, 17.6±3.5, and 19.4±4.6% inhibition for GIRK1/2, $n = 11$, 4, 4, and 4, respectively; 30.3±3.4, 18.8±1.3, 12.1±2.4, and 22.8±3.2% inhibition for GIRK1/4, $n = 13$, 5, 5, and 5, respectively). Additionally, the inhibitions were reversible with washout, similar to sertraline (data not shown). In contrast, Kir2.1 channels were insensitive to these drugs at 100 μM (less than 4% change of the Ba^{2+}-sensitive current components; 912.5±182.8 nA, $n = 4$). In uninjected oocytes, 300 μM of the drugs caused no significant response (less than 6 nA; $n = 4$ for each of the drugs). Altogether, the results suggest significant inhibition of GIRK channels by sertraline, duloxetine, and amoxapine, weak inhibition of the channels by nefazodone, mianserin, mirtazapine, and venlafaxine, and no significant effects of the drugs on Kir2.1 channels.



Figure 1. Inhibitory effects of sertraline on GIRK channels expressed in *Xenopus* oocytes. (A) In an oocyte injected with GIRK1 and GIRK2 mRNAs, current responses to 30 μM sertraline and 3 mM Ba^{2+} are shown. (B) In an oocyte injected with Kir2.1 mRNA, current responses to 100 μM sertraline and 3 mM Ba^{2+} are shown. (C) In an uninjected oocyte, no significant current responses to 300 μM sertraline or 3 mM Ba^{2+} are shown. Current responses were measured at a membrane potential of −70 mV in an hK solution that contained 96 mM K^+. Asterisks show the zero current level. Horizontal bars indicate the duration of application.
doi:10.1371/journal.pone.0028208.g001

Concentration-dependent inhibition of GIRK channels by various antidepressants

The concentration-response relationships for the inhibitory effects of different classes of antidepressants on GIRK1/2 and GIRK1/4 channels were investigated. Figure 2 shows that the inhibitions of both types of GIRK channels by various antidepressants were concentration-dependent with distinctive potency and effectiveness at micromolar concentrations. The rank order of the inhibition of GIRK channels by 100 μM of these drugs was the following: duloxetine≧sertraline>amoxapine>nefazodone>mianserin≧venlafaxine≈mirtazapine for GIRK1/2 channels and sertraline>duloxetine≫nefazodone, amoxapine>venlafaxine, mianserin>mirtazapine for GIRK1/4 channels. Table 1 shows the EC_{50} and n_H values obtained from the concentration-response relationships for sertraline, duloxetine and amoxapine, and the percentage inhibition of the GIRK currents by the drugs at the highest concentrations tested. Additionally, because the drugs could not completely block these types of GIRK channels even at the highest concentrations tested, the IC_{25} and IC_{50} values were also calculated to further compare the effects of the drugs (Table 1). The inhibition of GIRK1/2 channels by sertraline was similar to that by duloxetine (Fig. 2). Furthermore, the inhibition of GIRK1/2 channels by sertraline was statistically similar to the inhibition of GIRK1/4 channels ($P>0.05$ at each concentration, Tukey-Kramer *post hoc* test; Fig. 2, Table 1). In contrast, the inhibition of GIRK1/2 channels by duloxetine and amoxapine was more effective than the inhibition of GIRK1/4 channels ($P<0.05$ at 30, 100, and 300 μM for duloxetine and $P<0.05$ at 300, 500, and 1000 μM for amoxapine, Tukey-Kramer *post hoc* test; Fig. 2, Table 1).

Characteristics of inhibition of GIRK channels by the SSRI sertraline and SNRI duloxetine

Sertraline and duloxetine, which belong to commonly used classes of antidepressants, effectively inhibited GIRK channels, and we further investigated the effects of these drugs in more detail. Instantaneous GIRK1/2 currents elicited by the voltage step to −100 mV from a holding potential of 0 mV were diminished in the presence of 30 μM sertraline applied for 3 min (Fig. 3A). The percentage inhibition of the steady-state GIRK current at the end of the voltage step by sertraline was not significantly different from that of the instantaneous current ($P>0.05$, paired t-test; $n = 9$ at −40, −60, −80, −100, and −120 mV, respectively). For duloxetine, the instantaneous currents were primarily diminished in the presence of 30 μM duloxetine, and the currents gradually increased in the voltage step (Fig. 3A). The percentage inhibition of the steady-state GIRK current at the end of the voltage step by duloxetine significantly decreased compared with that of the instantaneous current ($P<0.05$ at −80, −100 and −120 mV, paired t-test, $n = 6$). Figure 3B shows that 30 μM sertraline- and duloxetine-sensitive currents in oocytes that expressed GIRK1/2 channels increased with negative membrane potentials, and the current-voltage relationships showed strong inward rectification ($n = 9$ and 6,



Figure 2. Concentration-response relationships for the effects of various antidepressants on GIRK1/2 and GIRK1/4 channels. The magnitudes of inhibition of GIRK currents by the drugs were compared with the 3 mM Ba^{2+}-sensitive current components in oocytes that expressed GIRK1/2 channels or GIRK1/4 channels (762.8±36.0 nA, n = 50, and 585.0±44.0 nA, n = 40, respectively). Each point and error bar represent the mean ± SEM of the percentage responses.
doi:10.1371/journal.pone.0028208.g002

respectively), similar to 3 mM Ba^{2+}-sensitive currents that corresponded to basal GIRK currents, indicating a characteristic of GIRK currents. The percentage inhibition of GIRK1/2 currents by 30 μM sertraline at the end of the voltage pulses showed no significant difference across voltages between −120 and −40 mV (no significant sertraline effect×membrane potential effect interaction, P>0.1, one-way ANOVA; P>0.1 across voltages, Tukey-Kramer *post hoc* test; Fig. 3C), suggesting voltage-independent inhibition of GIRK channels by sertraline. In contrast, the GIRK current inhibition by duloxetine at the end of the voltage pulses was voltage-dependent, with weaker inhibition at more negative membrane potentials (significant duloxetine effect×membrane potential effect interaction, P<0.05, one-way ANOVA; significant differences between −120 and −60 mV, between −120 and −40 mV, between −100 and −60 mV, and between −100 and −40 mV, P<0.05, Tukey-Kramer *post hoc* test, n = 6, Fig. 3C). The voltage-dependency was associated with a time-dependent decrease in the inhibition by duloxetine in the voltage pulses at more negative membrane potentials. Furthermore, similar results were obtained in oocytes that expressed GIRK1/4 channels (n = 4 for each of the drugs; data not shown). Altogether, sertraline and duloxetine primarily inhibited GIRK channels at the holding potential of 0 mV before the voltage pulses. The inhibitory effects of sertraline were voltage-independent and time-independent during each voltage pulse, whereas those of duloxetine decreased voltage-dependently with negative membrane potentials and time-dependently up to a steady state current level in each voltage pulse.

Furthermore, the effects of the two antidepressants on GIRK channels under a physiological K^+ condition were examined. In oocytes injected with GIRK1 and GIRK2 mRNAs, outward currents observed at a holding potential of −10 mV in a K4 solution that contained 4 mM K^+ were reversibly reduced by 30 μM sertraline (n = 4), 30 μM duloxetine (n = 4), and 3 mM Ba^{2+} (the Ba^{2+}-sensitive current components, 49.0±2.8 nA, n = 8; Fig. S1), whereas in uninjected oocytes, the drugs at 100 μM and 3 mM Ba^{2+} caused no significant response (3.0±0.9 nA for sertraline, 0±0 nA for duloxetine, and 7.6±1.3 nA for Ba^{2+}; n = 4, 4, and 8, respectively). The results suggest that the antidepressants also inhibited outward GIRK currents at a physiologically extracellular K^+ concentration.

Sertraline and duloxetine possess a secondary amine group with pK_a values of 8.9 and 9.34, respectively (Data Sheets of Pfizer and

Table 1. Inhibitory effects of sertraline, duloxetine and amoxapine on GIRK channels.

	Sertraline		*Duloxetine*		*Amoxapine*	
	GIRK1/2	**GIRK1/4**	**GIRK1/2**	**GIRK1/4**	**GIRK1/2**	**GIRK1/4**
EC_{50} (μM)	11.7±1.0	12.6±2.5	14.9±0.4	17.0±1.3	38.7±6.2	17.7±4.4
IC_{25} (μM)	6.9±0.6	7.0±1.0	6.6±0.6	12.6±1.2	21.5±8.3	39.7±15.8
IC_{50} (μM)	29.1±3.4	36.7±7.8	28.3±2.5	124.2±34.3	181.1±48.3	ND
% max	73.7±2.9	63.7±3.5	72.2±1.1	54.1±1.5	58.9±2.9	36.0±1.6
(μM; n)	(500; 16)	(300; 11)	(300; 7)	(300; 6)	(1000; 5)	(1000; 4)
n_H	1.02±0.05	0.89±0.09	0.94±0.06	0.97±0.07	0.87±0.03	0.87±0.07

Mean ± SEM concentrations of antidepressants (μM) that produce 50% of the maximal effect (EC_{50}) and are required to reduce basal GIRK currents by 25% and 50% (IC_{25} and IC_{50}, respectively) are shown. The % max values indicate the mean ± SEM percentage inhibition of basal GIRK currents by a drug at the highest concentrations tested. The highest concentrations tested (μM) and the number of oocytes tested (n) are shown in parentheses. The n_H values indicate the mean ± SEM of Hill coefficients. ND indicates that the value was not determined because of a low effectiveness of the drug.
doi:10.1371/journal.pone.0028208.t001



Figure 3. Characteristics of the inhibitory effects of sertraline and duloxetine on GIRK currents. (A) Representative GIRK1/2 currents elicited by a voltage step to −100 mV for 2 s from a holding potential of 0 mV in the presence or absence of 30 μM sertraline (left) or 30 μM duloxetine (right) applied for 3 min. Current responses were recorded in an hK solution that contained 96 mM K^+. Arrows indicate the zero current level. (B) Current-voltage relationships of the magnitudes of 3 mM Ba^{2+}-sensitive currents and the magnitudes of currents reduced by 30 μM sertraline (left, $n=9$) or 30 μM duloxetine (right, $n=6$) in oocytes that expressed GIRK1/2 channels. Current responses were normalized to the 3 mM Ba^{2+}-sensitive current component measured at a membrane potential of −100 mV (1851.0±220.4 nA, $n=15$). (C) Percentage inhibition of GIRK1/2 channels by 30 μM sertraline or 30 μM duloxetine over the voltage range of −120 to −40 mV. The magnitudes of inhibition of GIRK currents by 30 μM sertraline (left, $n=9$) and duloxetine (right, $n=6$) at the end of the voltage pulses were compared with the 3 mM Ba^{2+}-sensitive current components. All values are expressed as mean ± SEM.
doi:10.1371/journal.pone.0028208.g003

Eli Lilly and Company). At physiological pH or below, sertraline and duloxetine exist mainly in a protonated form, approximately 96.9% and 98.9% at pH 7.4, respectively, and the proportion of the uncharged form increases with an increase in pH. We examined whether changes in extracellular pH would affect GIRK channel inhibition by sertraline or duloxetine. However, in oocytes that expressed GIRK1/2 channels, the percentage inhibition of GIRK channels by sertraline or duloxetine at the same concentrations was not significantly affected by extracellular pH 7.4 and 9.0 (no significant pH×drug interaction, $P>0.05$, two-way ANOVA; $P>0.05$ at each concentration, Tukey-Kramer *post hoc* test; Fig. 4). The results indicate that a marked increase in the proportion of the uncharged form of sertraline and duloxetine may not significantly affect all of the inhibitory effects on GIRK channels, suggesting that GIRK channel inhibition may be mediated by both forms of the drugs with similar effectiveness. Additionally, the inhibition by the antidepressants was unlikely mediated by nonspecific membrane perturbation induced by the uncharged form.

Effects of sertraline on GIRK channels activated by GTPγS, a nonhydrolyzable GTP

GIRK channels are activated by various $G_{i/o}$-protein-coupled receptors through the direct action of G-protein βγ subunits



Figure 4. Concentration-dependent inhibition of GIRK channels by sertraline or duloxetine at different pH values. The magnitudes of inhibition of GIRK currents by the antidepressants were compared with the 3 mM Ba^{2+}-sensitive current components in oocytes that expressed GIRK1/2 channels (1020.8±96.2 nA at pH 7.4, $n=16$ for sertraline and $n=7$ for duloxetine; 1079.5±173.8 nA at pH 9.0, $n=7$ for sertraline and $n=6$ for duloxetine, respectively). Current responses were measured at a membrane potential of −70 mV in an hK solution that contained 96 mM K^+. Each point and error bar represent the mean ± SEM of the percentage responses.
doi:10.1371/journal.pone.0028208.g004

released from the heterotrimeric G-protein complex [32,33]. The effects of sertraline on GIRK channels activated by G-protein-coupled signaling mechanisms were further examined using GTPγS, a nonhydrolyzable GTP analog that maintains G-proteins in an activated state. Injection of GTPγS into *Xenopus* oocytes injected with GIRK1 and GIRK2 mRNAs increased inward currents with time and reached a steady-state level (516.0±123.7 nA, $n=5$) as reported previously [49,51]. The increased inward currents were completely blocked by 3 mM Ba^{2+}, whereas GTPγS injection into uninjected oocytes had no significant effect on current responses to 3 mM Ba^{2+} (3.9±2.1 nA, $n=5$). Increased GIRK currents composed of basal GIRK currents and GTPγS-induced GIRK currents were inhibited by sertraline ($IC_{25}=5.5\pm0.7$ μM; $IC_{50}=18.1\pm3.0$ μM; $n_H=1.24\pm0.09$; $n=5$; Fig. 5). The concentration response curve for the inhibition of total GIRK currents by sertraline was partially different from that for the inhibition of basal GIRK currents in GTPγS-untreated oocytes injected with GIRK1 and GIRK2 mRNAs ($P<0.05$ at 30 μM, Tukey-Kramer *post hoc* test, Fig. 5). The results suggest that the potency of the inhibition of GIRK channels activated by GTPγS-induced G-protein activation may be slightly higher than that of basally active GIRK channels, although the maximal efficacy was similar.



Figure 5. Effects of sertraline on total GIRK currents composed of GTPγS-induced and basal GIRK currents. For comparison, the effects on GTPγS-untreated basal GIRK currents shown in Figure 2 are also shown. The magnitudes of inhibition of GIRK currents by sertraline were compared with the 3 mM Ba^{2+}-sensitive current components. Each point and error bar represent the mean ± SEM of the percentage responses ($n=5$ for GTPγS-injected oocytes and $n=16$ for GTPγS-untreated oocytes). Current responses were measured at a membrane potential of −70 mV in an hK solution that contained 96 mM K^+.
doi:10.1371/journal.pone.0028208.g005

Sertraline inhibits ethanol-induced GIRK currents. GIRK channels are also activated by ethanol independent of G-protein signaling pathways [34]. Sertraline was shown to reduce ethanol consumption in mice [52] and was effective in alcoholics [53]. Therefore, we also examined the effects of sertraline on GIRK channel activation induced by ethanol. The effects of sertraline were evaluated by measuring the amplitude of the ethanol-induced current response during the extracellular application of sertraline at different concentrations. In oocytes injected with GIRK1 and GIRK2 mRNAs, the GIRK currents induced by 100 mM ethanol (344.2±40.3 nA, $n=6$) were reversibly attenuated in the presence of sertraline ($IC_{25}=6.2\pm1.4$ μM; $IC_{50}=29.6\pm5.5$ μM; $n_H=0.87\pm0.17$; $n=6$; Fig. 6A, 6B). However, the 100 mM ethanol-induced GIRK currents were not significantly affected by intracellularly applied sertraline (104.9±9.1% of untreated control current, paired *t*-test, $P>0.1$, $n=6$; Fig. 6C). Moreover, in oocytes that expressed GIRK channels, the basal currents were not substantially affected by intracellularly applied sertraline (92.5±1.6% of untreated control current, $n=6$). The results indicate that intracellular sertraline could not inhibit GIRK channels. In contrast, GIRK channel inhibition induced by extracellularly applied sertraline, which is mainly protonated at pH 7.4, was reversible with washout (Figs. 1A and 6A). Because the protonated form may not readily permeate the cell membrane, extracellularly applied sertraline may exist mainly on the extracellular side. Altogether, extracellular sertraline may inhibit GIRK channels activated by ethanol. Additionally, the extent of inhibition by sertraline of GIRK1/2 channels activated by ethanol was higher at 100 and 300 μM than that of basally active GIRK1/2 channels by G-proteins ($P<0.05$, Tukey-Kramer *post hoc* test), indicating a significant difference in the maximal efficacy of sertraline between ethanol activation of GIRK channels and G-protein activation of the channels.



Figure 6. Effect of sertraline on ethanol-induced GIRK currents. (A) Current responses to 100 mM ethanol (EtOH), 100 mM EtOH in the presence of 30 μM sertraline, and 100 mM EtOH in an oocyte injected with GIRK1 and GIRK2 mRNAs. Asterisk indicates the zero current level. Bars show the duration of application. (B) Concentration-dependent inhibition of EtOH-induced GIRK currents by sertraline. $I_{control}$ is the amplitude of GIRK currents induced by 100 mM EtOH (344.2±40.3 nA, $n=6$), and I is the current amplitude in the presence of sertraline. (C) Lack of effect of intracellular sertraline on 100 mM EtOH-induced GIRK currents. The amplitude of EtOH-induced GIRK currents after sertraline injection (black bar) was compared with EtOH-induced GIRK currents before the injection (control, white bar) in the same oocyte that expressed GIRK channels ($n=5$). Current responses were measured at a membrane potential of −70 mV in an hK solution that contained 96 mM K^+. All values are expressed as mean ± SEM.
doi:10.1371/journal.pone.0028208.g006

Discussion

The present study demonstrated that the SSRI sertraline, SNRI duloxetine, and second-generation TCA amoxapine effectively inhibited brain-type GIRK1/2 channels and cardiac-type GIRK1/4 channels expressed in *Xenopus* oocytes. However, the 5-HT_2 receptor antagonist nefazodone, SNRI venlafaxine, and NaSSAs mianserin and mirtazapine weakly inhibited both types of GIRK channels even at high concentrations. The inhibitions by different classes of antidepressants were concentration-dependent with various degrees of potency and effectiveness. In contrast, Kir2.1 channels in other Kir channel subfamilies were insensitive to all of the drugs. Furthermore, the present results suggest that sertraline and duloxetine primarily inhibited GIRK channels at the holding potential of 0 mV before the voltage pulses. The effects of sertraline on GIRK channels were voltage-independent and time-independent during each voltage pulse, similar to the effects of various TCAs [42]. The effects of duloxetine decreased voltage-dependently with negative membrane potentials and time-dependently up to a steady current level in each voltage pulse, and the voltage-dependency was associated with a time-dependent decrease in the inhibition by duloxetine at more negative membrane potentials. The present results also suggest that the site of action on the channels may be extracellular. In contrast, blockade of GIRK channels by extracellular Ba^{2+} and Cs^+, which occlude the pore of the open channel, increases concentration-dependently, voltage-dependently with negative membrane potentials, and time-dependently with a comparatively small effect on the instantaneous current but marked inhibition on the steady-state current at the end of the voltage pulses [27]. These observations suggest that sertraline and duloxetine may cause an allosteric conformational change in GIRK channels, rather than simple occlusion of the open channel. Additionally, sertraline may stably bind to the channels during the voltage pulses, whereas duloxetine may partially dissociate from the channels in the voltage pulses. The n_H values obtained from the concentration-response relationships for sertraline and duloxetine were almost 1 (Table 1), suggesting an one-to-one interaction between the drug and the binding site. Interestingly, GIRK channels were significantly inhibited by the SSRI sertraline and SNRI duloxetine, despite a great difference in the pharmacological profiles for monoamine transporters. The chemical structure of sertraline is distinct from that of duloxetine [2,54]. These antidepressants may act at different binding sites on the channels, and agents with similar structures may interact with GIRK channels. However, the SNRIs venlafaxine and milnacipran [43] had weak or little effects on GIRK channels, respectively. The distinctive effects of the SNRIs on GIRK channels may be attribute to their diverse chemical structures [54]. The *Xenopus* oocyte expression system is useful to determine drug actions on membrane proteins, such as voltage-gated Na^+ and Ca^{2+} channels, glutamate receptor channels, $5HT_{1C}$ receptor [55]. Since neuronal and cardiac GIRK channels are considered to consist predominantly of GIRK1/2 channels and GIRK1/4 channels, respectively [26,29,36], the effects of antidepressants on GIRK1/2 and

GIRK1/4 channels expressed in *Xenopus* oocytes were investigated in the present study. However, GIRK subunits have been suggested to form functional GIRK channels composed of several types of tetrameric stoichimetries in various cell populations, particularly neurons [56]. GIRK1 subunits are posttranslationally modified by glycosylation [26,56,57]. Furthermore, GIRK channels are regulated by not only G proteins but also phosphatidylinositol 4,5-bisphosphate in the cell membrane, polyamines and protein kinases [33]. The effects of antidepressants on GIRK channels might be influenced by differences in composition of the channel subunits, levels of glycosylation of GIRK1 subunits, and interaction with membrane and intracellular factors between the *Xennopus* oocyte expression system and neurons. Further studies using neurons and cardiac myocytes may be useful for advancing our understanding of the effects of antidepressants on GIRK channels.

The therapeutic serum concentrations range from approximately 0.16 to 0.82 μM for sertraline, 0.07 to 0.27 μM for duloxetine, 0.57 to 1.9 μM for amoxapine, 0.02 to 0.64 μM for nefazodone, 0.06 to 0.26 μM for mianserin, 0.08 to 0.37 μM for mirtazapine, and 0.72 to 1.44 μM for venlafaxine [2,58–60]. Additionally, increases in antidepressant doses are associated with increases in blood concentrations [59]. The concentrations in cases of overdose were reported to reach up to 13.7 μM for sertraline [61], 8.4 μM for duloxetine [62], 57.4 μM for amoxapine [63], 11.7 μM for nefazodone, 18.9 μM for mianserin [59], 8.7 μM for mirtazapine [64], and 302.8 μM for venlafaxine [65]. Most of the doses of antidepressants are distributed in various tissues from the blood, and antidepressants generally accumulate in the brain [2,58,66]. Indeed, brain levels of antidepressants were 40-fold higher for sertraline [67], 15-fold higher for duloxetine [68], 8.7- to 35.5-fold higher for amoxapine [69], 1.3- to 1.8-fold higher for nefazodone [70], 12.1-fold higher for mianserin [71], 3.2-fold higher for mirtazapine, and 4.9-fold higher for venlafaxine [66] compared with blood levels. Altogether, due to the high brain-to-blood partition ratios, presumed brain concentrations during treatment with therapeutic doses would range from approximately 6.4 to 32.8 μM for sertraline and 5.0 to 67.5 μM for amoxapine, and those after overdose would reach up to 548 μM for sertraline, 126 μM for duloxetine, 499 or 2038 μM for amoxapine, 229 μM for mianserin, and 1484 μM for venlafaxine. In addition, it has been shown that the therapeutic concentrations of some SSRIs in the brain were much higher than binding affinities of the antidepressants to monoamine transportors [72–75]. Brain concentrations at therapeutic doses of sertraline and amoxapine and after overdose of sertraline, duloxetine, amoxapine, mianserin and venlafaxine overlap with their effective concentrations in inhibiting predominant brain-type GIRK1/2 channels (Fig. 2). Therefore, the present results suggest that some inhibition of GIRK channels in the brain might occur with the antidepressant medication, particularly sertraline. However, mirtazapine and nefazodone may have small or little effects on GIRK channels even at toxic levels. Inhibition of GIRK channels causes a depolarization of membrane potential, resulting in an increase in cell excitability [38]. GIRK channels play an important role in regulating neuronal excitability and synaptic transmission [36,41]. Therefore, even partial inhibition of GIRK channels by the antidepressants may affect various brain functions.

Interestingly, GIRK2 knockout mice exhibit reduced anxiety-related behavior [76]. Animal studies have shown that sertraline has anxiolytic properties [77,78]. Indeed sertraline is clinically effective in the treatment of panic disorder and posttraumatic stress disorder [79]. Although the therapeutic effects are generally thought to be primarily attributable to inhibition of serotonin reuptake in the brain [2], some inhibition of GIRK channels might also contribute to improvement of anxiety symptoms.

Although the risk of seizures with antidepressants is generally very low, the association with overdose is well established [80]. However, the molecular mechanisms by which antidepressants cause seizures have not been clarified. GIRK2 knockout mice exhibit spontaneous seizures and are more susceptible to seizures induced by pentylenetetrazol than wild-type mice [37]. The risk of seizures in overdoses with sertraline, duloxetine, mianserin, and venlafaxine significantly increases [80–82], and amoxapine overdose is more likely to cause seizures [83]. Brain levels of the drugs in overdose cases may be considerably higher than levels during treatment at therapeutic doses, suggesting significant inhibition of neuronal GIRK channels by the drugs. Additionally, other types of K^+ channels are inhibited by antidepressants at micromolar concentrations, that is, the two-pore-domain K^+ channel, TREK-1 for sertraline and voltage-gated K^+ channels for amoxapine and mianserin [16,17,21]. Therefore, the inhibition of GIRK channels by the drugs after overdose together with the different types of K^+ channels may contribute to increased seizure activity and the occurrence of other neurological side effects by increasing neuronal excitability.

In the heart, GIRK channels cause a slowing of heart rate in response to activation of M_2 muscarinic receptors through acetylcholine release from the stimulated vagus nerve [25,26]. GIRK1 and GIRK4 knockout mice exhibit slightly elevated resting heart rates [39]. The present results indicate that sertraline, duloxetine, amoxapine, and venlafaxine can partially inhibit cardiac-type GIRK1/4 channels at blood levels after overdose, although the corresponding heart concentrations were not determined. These antidepressants are associated with sinus tachycardia in cases of toxicity after overdose [81,82,84,85]. In addition, the drugs exhibit low micromolar binding affinities for the muscarinic receptor, with the exception of venlafaxine [2,86], and nanomolar to low micromolar binding affinities for norepinephrine transporters [2,68]. Altogether, sinus tachycardia associated with drug overdose may be related to partial inhibition of atrial GIRK channels as well as antagonism of the muscarinic receptor and enhancement of sympathetic nerve activity.

Sertraline was shown to be effective in the treatment of alcoholics [53]. Interestingly, GIRK2 knockout mice show reduced ethanol-induced conditioned taste aversion and conditioned place preference and are less sensitive than wild-types to some of the acute effects of ethanol, including anxiolysis, habituated locomotor stimulation, and acute handling-induced convulsions [76,87]. In the present study, sertraline inhibited ethanol-induced GIRK1/2 currents. Sertraline may suppress some of the GIRK-related effects of ethanol. Furthermore, GIRK knockout mice show an attenuation of the morphine withdrawal syndrome [88]. Sertraline reduced the severity of the naloxone-precipitated opioid withdrawal syndrome in rats [89]. GIRK knockout mice also show reduced cocaine self-administration [90]. Inhibition of GIRK channels by sertraline may play a role in the treatment of addiction to these drugs.

Supporting Information

Figure S1 Effect of sertraline on outward GIRK currents. In a *Xenopus* oocyte injected with GIRK1 and GIRK2 mRNAs, current responses to 30 μM sertraline and 3 mM Ba^{2+} at a membrane potential of −10 mV in a K4 solution that contained 4 mM K^+ are shown. Asterisk indicates the zero current level.
(DOC)

Acknowledgments

We are grateful to Dr. Kansaku Baba for his cooperation and Mr. Kazuo Kobayashi (Niigata University) for his assistance. We also thank Dr. Lily Y. Jan (University of California, San Francisco) for generously providing the Kir2.1 cDNA.

Author Contributions

Conceived and designed the experiments: TK. Performed the experiments: TK. Analyzed the data: TK KW KI. Contributed reagents/materials/analysis tools: TK KW KI. Wrote the paper: TK KI.

References

1. Kent JM (2000) SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 355: 911–918.
2. Baldessarini RJ (2001) Drugs and the treatment of psychiatric disorders: depression and anxiety disorders. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th edn. New York: McGraw-Hill. pp 447–483.
3. Mann JJ (2005) The management of depression. N Engl J Med 353: 1819–1834.
4. Ni YG, Miledi R (1997) Blockage of $5HT_{2C}$ serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci USA 94: 2036–2040.
5. Fan P (1994) Effects of antidepressants on the inward current mediated by 5-HT_3 receptors in rat nodose ganglion neurones. Br J Pharmacol 112: 741–744.
6. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, et al. (2002) Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 7: 525–535.
7. Sernagor E, Kuhn D, Vyklicky L, Jr., Mayer ML (1989) Open channel block of NMDA receptor responses evoked by tricyclic antidepressants. Neuron 2: 1221–1227.
8. Nakazawa K, Inoue K, Ohno Y (1999) Block and unblock by imipramine of cloned and mutated $P2X_2$ receptor/channel expressed in *Xenopus* oocytes. Neurosci Lett 264: 93–96.
9. Ogata N, Yoshii M, Narahashi T (1989) Psychotropic drugs block voltage-gated ion channels in neuroblastoma cells. Brain Res 476: 140–144.
10. Mathie A, Wooltorton JRA, Watkins CS (1998) Voltage-activated potassium channels in mammalian neurons and their block by novel pharmacological agents. Gen Pharmacol 30: 13–24.
11. Pancrazio JJ, Kamatchi GL, Roscoe AK, Lynch C, III (1998) Inhibition of neuronal Na^+ channels by antidepressant drugs. J Pharmacol Exp Ther 284: 208–214.
12. Teschemacher AG, Seward EP, Hancox JC, Witchel HJ (1999) Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 128: 479–485.
13. Deák F, Lasztóczi B, Pacher P, Petheö GL, Kecskeméti V, et al. (2000) Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells. Neuropharmacology 39: 1029–1036.
14. Choi BH, Choi J-S, Yoon SH, Rhie D-J, Min DS, et al. (2001) Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1. Neuropharmacology 41: 443–453.
15. Cuellar-Quintero JL, García DE, Cruzblanca H (2001) The antidepressant imipramine inhibits the M-type K^+ current in rat sympathetic neurons. Neuroreport 12: 2195–2198.
16. Scherer D, von Löwenstern K, Zitron E, Scholz EP, Bloehs R, et al. (2008) Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin. Naunyn-Schmiedeberg's Arch Pharmacol 378: 73–83.
17. He Y-L, Zhan X-Q, Yang G, Sun J, Mei Y-A (2010) Amoxapine inhibits the delayed rectifier outward K^+ current in mousse cortical neurons via cAMP/protein kinase A pathways. J Pharmacol Exp Ther 332: 437–445.
18. Lee K, McKenna F, Rowe ICM, Ashford MLJ (1997) The effects of neuroleptic and tricyclic compounds on BK_{Ca} channels activity in rat isolated cortical neurones. Br J Pharmacol 121: 1810–1816.
19. Dreixler JC, Bian J-T, Cao Y-J, Roberts MT, Roizen JD, et al. (2000) Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds. Eur J Pharmacol 401: 1–7.
20. Terstappen GC, Pula G, Carignani C, Chen MX, Roncarati R (2001) Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines. Neuropharmacology 40: 772–783.
21. Heurteaux C, Lucas G, Guy N, Yacoubi ME, Thümmler S, et al. (2006) Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci 9: 1134–1141.
22. Maertens C, Droogmans G, Verbesselt R, Nilius B (2002) Block of volume-regulated anion channels by selective serotonin reuptake inhibitors. Naunyn-Schmiedeberg's Arch Pharmacol 366: 158–165.
23. Maertens C, Wei L, Voets T, Droogmans G, Nilius B (1999) Block by fluoxetine of volume-regulated anion channels. Br J Pharmacol 126: 508–514.
24. Reimann F, Ashcroft FM (1999) Inwardly rectifying potassium channels. Curr Opin Cell Biol 11: 503–508.
25. Kubo Y, Reuveny E, Slesinger PA, Jan YN, Jan LY (1993) Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel. Nature 364: 802–806.
26. Krapivinsky G, Gordon EA, Wickman K, Velimirovic B, Krapivinsky L, et al. (1995) The G-protein-gated atrial K^+ channel I_{KACh} is a heteromultimer of two inwardly rectifying K^+-channel proteins. Nature 374: 135–141.
27. Lesage F, Guillemare E, Fink M, Duprat F, Heurteaux C, et al. (1995) Molecular properties of neuronal G-protein-activated inwardly rectifying K^+ channels. J Biol Chem 270: 28660–28667.
28. Karschin C, Dißmann E, Stuhmer W, Karschin A (1996) IRK(1–3) and GIRK(1–4) inwardly rectifying K^+ channel mRNAs are differentially expressed in the adult rat brain. J Neurosci 16: 3559–3570.
29. Liao YJ, Jan YN, Jan LY (1996) Heteromultimerization of G-protein-gated inwardly rectifying K^+ channel proteins GIRK1 and GIRK2 and their altered expression in *weaver* brain. J Neurosci 16: 7137–7150.
30. Inanobe A, Yoshimoto Y, Horio Y, Morishige K-I, Hibino H, et al. (1999) Characterization of G-protein-gated K^+ channels composed of Kir3.2 subunits in dopaminergic neurons of the substantia nigra. J Neurosci 19: 1006–1017.
31. North RA (1989) Drug receptors and the inhibition of nerve cells. Br J Pharmacol 98: 13–28.
32. Dascal N (1997) Signalling via the G protein-activated K^+ channels. Cell Signal 9: 551–573.
33. Kobayashi T, Ikeda K (2006) G protein-activated inwardly rectifying potassium channels as potential therapeutic targets. Curr Pharm Des 12: 4513–4523.
34. Kobayashi T, Ikeda K, Kojima H, Niki H, Yano R, et al. (1999) Ethanol opens G-protein-activated inwardly rectifying K^+ channels. Nat Neurosci 2: 1091–1097.
35. Lewohl JM, Wilson WR, Mayfield RD, Brozowski SJ, Morrisett RA, et al. (1999) G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action. Nat Neurosci 2: 1084–1090.
36. Lüscher C, Jan LY, Stoffel M, Malenka RC, Nicoll RA (1997) G protein-coupled inwardly rectifying K^+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron 19: 687–695.
37. Signorini S, Liao YJ, Duncan SA, Jan LY, Stoffel M (1997) Normal cerebellar development but susceptibility to seizures in mice lacking G protein-coupled, inwardly rectifying K^+ channel GIRK2. Proc Natl Acad Sci USA 94: 923–927.
38. Kuzhikandathil EV, Oxford GS (2002) Classic D1 dopamine receptor antagonist *R*-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine hydrochloride (SCH23390) directly inhibits G protein-coupled inwardly rectifying potassium channels. Mol Pharmacol 62: 119–126.
39. Bettahi I, Marker CL, Roman MI, Wickman K (2002) Contribution of the Kir3.1 subunit to the muscarinic-gated atrial potassium channel I_{KACh}. J Biol Chem 277: 48282–48288.
40. Hashimoto N, Yamashita T, Tsuruzoe N (2006) Tertiapin, a selective IK_{ACh} blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation. Pharmacol Res 54: 136–141.
41. Lüscher C, Slesinger PA (2010) Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. Nat Rev Neurosci 11: 301–315.
42. Kobayashi T, Washiyama K, Ikeda K (2004) Inhibition of G protein-activated inwardly rectifying K^+ channels by various antidepressant drugs. Neuropsychopharmacology 29: 1841–1851.
43. Kobayashi T, Washiyama K, Ikeda K (2006) Inhibition of G protein-activated inwardly rectifying K^+ channels by the antidepressant paroxetine. J Pharmacol Sci 102: 278–287.
44. Kobayashi T, Ikeda K, Ichikawa T, Abe S, Togashi S, et al. (1995) Molecular cloning of a mouse G-protein-activated K^+ channel (mGIRK1) and distinct distributions of three GIRK (GIRK1, 2 and 3) mRNAs in mouse brain. Biochem Biophys Res Commun 208: 1166–1173.
45. Kobayashi T, Ikeda K, Kumanishi T (2000) Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K^+ (GIRK) channels expressed in *Xenopus* oocytes. Br J Pharmacol 129: 1716–1722.
46. Kubo Y, Baldwin TJ, Jan YN, Jan LY (1993) Primary structure and functional expression of a mouse inward rectifier potassium channel. Nature 362: 127–133.
47. Kobayashi T, Ikeda K, Kumanishi T (2002) Functional characterization of an endogenous *Xenopus* oocyte adenosine receptor. Br J Pharmacol 135: 313–322.
48. Ikeda K, Yoshii M, Sora I, Kobayashi T (2003) Opioid receptor coupling to GIRK channels: in vitro studies using a Xenopus oocyte expression system and in vivo studies on weaver mutant mice. Methods Mol Med 84: 53–64.
49. Kovoor A, Henry DJ, Chavkin C (1995) Agonist-induced desensitization of the mu opioid receptor-coupled potassium channel (GIRK1). J Biol Chem 270: 589–595.
50. Kobayashi T, Washiyama K, Ikeda K (2003) Inhibition of G protein-activated inwardly rectifying K^+ channels by fluoxetine (Prozac). Br J Pharmacol 138: 1119–1128.
51. Kobayashi T, Washiyama K, Ikeda K (2010) Inhibition of G-protein-activated inwardly rectifying K^+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine. Neuropsychopharmacology 35: 1560–1569.